癌症研究
癌症干细胞
间质细胞
下调和上调
肿瘤微环境
癌症
膀胱癌
癌相关成纤维细胞
癌细胞
肿瘤进展
生物
医学
内科学
生物化学
基因
肿瘤细胞
作者
Junlong Zhuang,Lan Shen,Meiqian Li,Jingya Sun,Jiange Hao,Jiaxuan Li,Zhen Zhu,Shuning Ge,Dianzheng Zhang,Hongqian Guo,Ruimin Huang,Jun Yan
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2023-03-20
卷期号:83 (10): 1611-1627
被引量:43
标识
DOI:10.1158/0008-5472.can-22-2213
摘要
Abstract Cancer stem-like cells (CSC) play pivotal roles in both chemoresistance and recurrence of many cancer types, including urothelial bladder cancer (UBC). In addition to intrinsic signaling pathways, extracellular cues from the tumor microenvironment (TME) are indispensable for the maintenance of CSCs. To better understand the mechanisms involved in TME-mediated generation and support of UBC CSCs, we focused on the role of cancer-associated fibroblasts (CAF) in this study. Overexpression of miR-146a-5p in CAFs promoted CAF-to-UBC cell interactions, cancer stemness, and chemoresistance to treatment with gemcitabine and cisplatin. Mechanistically, miR-146–5p upregulated SVEP1 in CAFs by enhancing the recruitment of transcriptional factor YY1. Meanwhile, by targeting the 3′UTR of mRNAs of ARID1A and PRKAA2 (also known as AMPKα2) in UBC cells, CAF-secreted miR-146a-5p promoted cancer stemness and chemoresistance. Downregulation of ARID1A resulted in the inhibition of SOCS1 and subsequent STAT3 activation, and downregulated PRKAA2 led to the activation of mTOR signaling. Elevated levels of exosomal miR-146a-5p in the serum of patients with UBC were correlated with both tumor stage and relapse risk. These findings altogether indicate that CAF-derived miR-146a-5p can promote stemness and enhance chemoresistance in UBC. Exosomal miR-146a-5p may be a biomarker of UBC recurrence and a potential therapeutic target. Significance: The tumor–stromal cross-talk mediated by cancer-associated fibroblast–derived miR-146a-5p fosters cancer stem cell niche formation and cancer stemness to drive chemoresistance in urothelial bladder cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI